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ABSTRACT
Objective Several studies have demonstrated a
favourable safety profile for thiopurine use for
inflammatory bowel disease (IBD) during pregnancy. We
performed a study in pregnant patients with IBD who
were using thiopurines, in order to determine the
influence of pregnancy on thiopurine metabolism and to
assess intrauterine exposure of the fetus to thiopurines.
Design Female patients with IBD receiving steady-state
thiopurines and planning a pregnancy were prospectively
enrolled. 6-Thioguanine nucleotide (6-TGN) and 6-
methylmercaptopurine (6-MMP) concentrations were
determined, combined with routine laboratory tests,
before, during and after pregnancy. Thiopurine
metabolites were measured in umbilical cord blood
immediately after delivery.
Results Thirty patients who were using azathioprine
(28 patients, median dose 1.93 mg/kg) or mercaptopurine
(two patients, doses 1.32 and 0.94 mg/kg) were included.
During pregnancy, median 6-TGN decreased over time
(p=0.001). while 6-MMP increased, without causing
myelotoxicity or hepatotoxicity. After delivery, both 6-TGN
and 6-MMP levels returned to preconception baseline
levels. Fetal 6-TGN concentrations correlated positively with
maternal 6-TGN levels (p<0.0001). No 6-MMP was
detected in the newborns, except one born with
pancytopenia and high alkaline phosphatase activity; the
mother of this infant had severe pre-eclampsia. All infants
had normal Apgar scores, but 60% had anaemia at birth.
No major congenital abnormalities were observed.
Conclusions Pregnancy has a major effect on maternal
thiopurine metabolism. In utero the unborn child is
exposed to 6-TGN, but not to 6-MMP. Sixty per cent of the
infants were born with anaemia, which raises the question
whether infants should be tested for possible anaemia
immediately after birth.
INTRODUCTION
Conventional immune-modulating thiopurines such
as mercaptopurine (MP) and its pro-drug,
azathioprine (AZA), have proven efficacy in the
treatment of inflammatory bowel disease (IBD),
both inducing and, especially, maintaining clinical
remission.1–3 Patients with IBD treated with thio-
purines are often in their reproductive years, as
IBD predominantly occurs in the second to third
decade of life.4 5 Although animal studies have
suggested that thiopurines may be teratogenic,
several human studies have shown a good safety
profile for thiopurine use during pregnancy in
patients with IBD.6–10 However, the safety profile
has to be balanced against the potential risks of
disease relapse for mother and fetus if thiopurines
are withdrawn, since a flare of IBD is associated
with an increased risk of lower birth weight or
preterm birth.11 12
In a small pilot study, our research group demon-
strated in vivo that the fetus is exposed to the
pharmacologically active 6-thioguanine nucleotides
(6-TGN) generated by maternal AZA use.
Interestingly, no 6-methylmercaptopurine (6-MMP)
was detected in red blood cells (RBCs) of the three
infants studied.13
Significance of this study
What is already known about this subject?
▸ Thiopurine use during pregnancy is relatively
safe.
▸ The placenta forms a barrier to azathioprine
and its metabolites.
What are the new findings?
▸ Pregnancy has a major effect on thiopurine
metabolism without development of
myelotoxicity or hepatotoxicity.
▸ The fetus is exposed to the pharmacologically
active 6-thioguanine nucleotides, but not to
6-methylmercaptopurine.
▸ Sixty per cent of infants are born with mild
anaemia, probably due to maternal thiopurine
use.
How might it impact on clinical practice in
the foreseeable future?
▸ Monitoring maternal thiopurine metabolite
concentration during pregnancy may allow
avoidance of high fetal 6-thioguanine
nucleotide levels.
▸ Infants exposed to maternal thiopurine use
during pregnancy should be routinely examined
for signs of anaemia immediately after birth.
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Prospective data on pharmacokinetic effects of pregnancy on
thiopurine metabolism are lacking. Therefore, the aims of this
study of female patients with IBD were to examine the influence
of pregnancy on thiopurine metabolism and determine intra-
uterine exposure to thiopurine metabolites and its potentially
toxic effect on pregnancy outcome.
MATERIALS AND METHODS
Patient population and baseline characteristics
Female patients with IBD aged 18–45 years, who were receiving
steady-state AZA or MP for at least 8 consecutive weeks and
planning a pregnancy, were eligible for this prospective, Dutch
multicentre study. Patients were included between January 2006
and January 2011. The study was approved by the medical
ethics committee of all participating hospitals. All patients gave
informed consent. Exclusion criteria were: concomitant use of
allopurinol, ACE inhibitors or furosemide; bone marrow sup-
pression (leucocyte and/or platelet count lower than the lower
reference limit); presence of active inflammation (C-reactive
protein >1× upper normal limit in combination with fever);
anaemia (haemoglobin concentration lower than the lower refer-
ence limit); impaired renal function (serum creatinine >2×
upper normal limit); elevated liver function tests (>2× upper
normal limit); known cardiac failure (New York Heart
Association scale, grade III–IV); a blood transfusion received
within the last 3 months; requested/planned delivery at home.
At baseline, the following data on patient characteristics were
collected: weight, length, smoking, alcohol use, type of IBD
(Crohn’s disease (CD), ulcerative colitis (UC) or unclassified),
duration of IBD at baseline, IBD localisation, nature of IBD, type
and dose of thiopurine, and co-medication. All patients with UC
or CD were classified according to the Montreal classification.14
Thiopurine metabolite levels and toxicity of thiopurines
during pregnancy
6-TGN and 6-MMP were measured in RBCs by the validated
method of Shipkova et al,15 which is a modification of the
method of Dervieux et al.16 The blood samples obtained in
lithium tubes sprayed with heparin were sent to the pharmacy
department of the VU University Medical Center for determin-
ation of thiopurine metabolites. To minimise the risk of thiopur-
ine metabolite concentrations decreasing because of their
limited chemical stability, all samples were immediately stored at
4°C until shipment.17 Upon arrival at the pharmacy department,
RBCs were washed and stored at −20°C until analysis. In each
sample, RBCs were isolated from the 7 ml of drawn blood,
yielding an RBC count of ∼3.5×1012/l (range 2.5–4.5×1012/l).
In the 250 ml used for analysis, there were on average 8.8×108
RBCs. Metabolite concentrations were subsequently expressed
in pmol/8×108 RBCs. A reversed-phase gradient high-
performance liquid chromatography system was used to separate
6-TGN and 6-MMP.17 The lower limit of detection of 6-TGN
and 6-MMP was 30 and 100 pmol/8×108 RBCs, respectively.
To compare our data with previously published studies of
patients with IBD, in which the method developed by Lennard
and Singleton18 was usually used to determine thiopurine meta-
bolites, 6-TGN concentrations were divided by 2.6.15 By means
of this conversion, the concentrations derived with the method
of Dervieux et al can be compared with Lennard-based levels
(correlation coefficient r=0.99).15 Throughout this article, these
converted metabolite levels (and thus comparable with data gen-
erated by the method of Lennard and Singleton) will be primar-
ily used. The outcomes according to both methods will be
tabulated.
Thiopurine metabolite levels were measured at baseline (before
pregnancy), directly after confirmation of pregnancy, at the end
of the first and second trimesters, at delivery, and 3 months after
delivery. Thiopurine dose was not changed throughout the study
period. During these six planned visits, blood was routinely
drawn to assess potential thiopurine-induced biochemical toxicity
(eg, myelotoxicity, hepatotoxicity). Hepatotoxicity in the mothers
was defined as twice the upper limit of alanine transaminase
(ALT), aspartate transaminase (AST), alkaline phosphatase (AP) or
γ-glutamyltransferase (γ-GT) activity or more. Myelotoxicity in
the mothers was defined as the presence of leucopenia, thrombo-
cytopenia or a haemoglobin level below the lower reference limit
according to the WHO.
Intrauterine exposure to thiopurine metabolites and toxicity
in infants
To determine intrauterine exposure to thiopurine therapy, blood
was drawn from the artery and vein of the umbilical cord imme-
diately after delivery. 6-TGN and 6-MMP levels were deter-
mined in these samples.17 In addition, blood was routinely
drawn from infants to assess potential toxicity (hepatotoxicity
and bone marrow depression) due to maternal use of thiopur-
ines. In newborns, leucopenia was defined as a leucocyte count
below 5×109/l, anaemia as a haemoglobin level below
10 mmol/l, and thrombocytopenia as a thrombocyte count
below 150×109/l.19 Hepatotoxicity in newborns was defined as:
ALT>50 U/l, AST>140 U/l, AP>300 U/l or γ-GT>263 U/l.20
PREGNANCY OUTCOME
Data on pregnancy outcome included gestational age, premature
births (gestational age <37 weeks), birth weight, caesarean
section, congenital malformations and spontaneous abortion.
Statistical analysis
Demographic data are given descriptively and are tabulated.
Data are expressed as median (IQR) according to distribution.
The Spearman rank correlation coefficient was used to assess
correlations. The Friedman test was used to assess statistically
significant differences in thiopurine metabolite concentration
over time during pregnancy. Post hoc analysis was conducted
with the Wilcoxon signed-rank test for paired data. A p value
less than 0.05 was considered significant. SPSS Version 17.0 was
used for statistical analysis.21
RESULTS
Patient population and baseline characteristics
In total, 59 female patients with IBD were included on the basis
of their expressed wish to become pregnant. Of these patients,
41 (69%) became pregnant. Seven patients had a miscarriage in
the first trimester, while another three had a spontaneous abor-
tion in the second trimester. One patient was lost to follow-up.
In total, 30 patients had a successful pregnancy outcome and
were further analysed for the purpose of this study. Patient char-
acteristics of these 30 patients are given in table 1. Median age
of the patients was 30 years (IQR 27–33). CD and UC were
diagnosed in 24 (80%) and six (20%) patients, respectively.
Median duration of IBD at the time of inclusion was 8.5 years
(IQR 6.0–12.0).
Characteristics of thiopurine therapy are also provided in
table 1. Twenty-eight patients were receiving steady-state AZA
at a median dose of 1.93 mg/kg (IQR 1.46–2.23). Two
patients were receiving steady-state MP at a dose of 1.32 and
0.94 mg/kg, respectively.
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Thiopurine levels and toxicity during pregnancy
Overall, a statistically significant decrease in median 6-TGN
levels was observed during pregnancy (p=0.001). After delivery,
median 6-TGN levels returned to preconception baseline levels
(figure 1 and table 2). In contrast, median 6-MMP levels
increased during pregnancy, but the increase was not significant
(p=0.183). 6-MMP levels had returned to preconception base-
line concentrations 3 months after delivery (figure 2 and table
2). In 10% of the women, only a slight alteration or no change
in 6-MMP or 6-TGN levels was observed during pregnancy.
Median 6-MMP/6-TGN ratios increased significantly during
pregnancy (p=0.007). After delivery, the ratio decreased to pre-
conception baseline levels (figure 3 and table 2). The significant
differences in thiopurine metabolite concentration during preg-
nancy and post partum compared with preconception values are
shown in table 3. In none of the 30 patients were biochemical
signs of myelotoxicity or hepatotoxicity observed during preg-
nancy. All patients tolerated thiopurine therapy well and no
adverse events were reported.
There was no clear difference in recalculated 6-TGN levels
between patients with a full-term pregnancy and patients who
had a miscarriage in the first trimester (106 vs 96 pmol/8×108
RBCs, respectively) or spontaneous abortion in the second tri-
mester (85 vs 96 pmol/8×108 RBCs, respectively). However,
there was a difference in 6-MMP levels between patients with a
full-term pregnancy and patients who had a miscarriage in the
first trimester (2140 vs 340 pmol/8×108 RBCs, respectively).
The 6-MMP levels in the second trimester in women with a full-
term pregnancy and those who had a spontaneous abortion
were equivalent (2330 vs 2830 pmol/8×108 RBCs, respec-
tively). No further statistical tests were performed, as the groups
of patients were too small for proper analysis.
Thiopurine levels and blood results in infants
Thirty women gave birth to 31 infants, as one pregnancy
resulted in twins. Because of technical or logistic problems,
umbilical cord blood was not drawn from six infants.
Therefore, thiopurine metabolites were determined in 25/31
infants (81%). Median 6-TGN concentration was lower in the
newborn infants than in mother at the time of delivery: 42 vs
92 pmol/8×108 RBCs, p=0.01 (equivalent to the originally
measured 100 vs 240 pmol/8×108 RBCs, according to the
method of Dervieux et al). 6-TGN levels in the infants corre-
lated strongly and positively with 6-TGN levels in the mother
(Spearman correlation r=0.74, p<0.0001) (figure 4). No
6-MMP was detected in 24 of the 25 infants (96%).
The remaining infant had a 6-MMP concentration of
1290 pmol/8×108 RBCs and a 6-TGN level of 65 pmol/8×108
RBCs; this child was born with pancytopenia and a 10-fold
increased AP activity at a gestational age of 38 weeks. The
mother of this infant had a 6-MMP concentration of
2200 pmol/8×108 RBCs during delivery. She received inflixi-
mab combined with AZA until 29 weeks of gestation and devel-
oped severe pregnancy pre-eclampsia, leading to early hospital
admittance. Haemoglobin level was measured in 16 of the 31
(52%) newborns. Ten of these (63%) had anaemia at birth
(median haemoglobin level 9.25 mmol/l (IQR 8.25–9.60)). Two
of these children had combined anaemia and thrombocytopenia.
Median 6-TGN concentration was higher in infants with
anaemia than in those without: 100 vs 35 pmol/8×108 RBCs,
respectively, p=0.22 (260 vs 90 pmol/8×108 RBCs, respectively,
according to the method of Dervieux et al). All newborns with
anaemia had normal Apgar scores immediately after birth. AP
activity was measured in 12 of the 31 newborns. Three of these
(25%) had an isolated AP activity above the reference limit;
Figure 1 Maternal 6-thioguanine nucleotide (6-TGN) levels. A
significant decrease in median maternal 6-TGN (indicated by horizontal
lines) was observed during pregnancy (p=0.001). After delivery, 6-TGN
levels returned to baseline concentrations (Wilcoxon, T=0 vs T=5,
p>0.05). 6-TGN concentration (pmol/8×108 red blood cells (RBC)) is
depicted on the y-axis. T=0, before conception; T=1, directly after
pregnancy confirmation; T=2, after the first trimester; T=3, after the
second trimester; T=4, delivery; T=5, 3 months after delivery. 6-TGN
concentrations are expressed in converted values (comparable with
data generated according to the method of Lennard).
Table 1 Patient characteristics (mothers) (total=30)
Characteristic Value
Age (years) 30 (27–33)
Weight (kg) 70 (57–78)
Smoking at inclusion 5
Alcohol use at inclusion 9
Disease (CD/UC) 24/6
Montreal classification of UC patients (n=6)
E2 3
E3 3








Dose of AZA (mg/kg) 1.93 (1.46–2.23)









Values are number or median (IQR).
AZA, azathioprine; CD, Crohn’s disease; IBD, inflammatory bowel disease; MP,
mercaptopurine; UC, ulcerative colitis.
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however, all three infants were born prematurely. No 6-MMP
was detected in these three children. There was no significant
difference in 6-TGN concentrations in blood obtained from the
umbilical vein compared with the umbilical artery.
Mode of delivery, infant characteristics and congenital
abnormalities
A caesarean section was performed in 14 of the 30 (47%)
mothers. Ten (71%) had an elective caesarean section. Reasons
were perianal disease, history of abdominal or vaginal surgery,
previous caesarean section, and pre-eclampsia. All emergency
caesarean sections (n=4) were performed because of fetal dis-
tress. Median gestational age was 39 weeks (IQR 38–40.1), and
median birth weight was 3410 g (IQR 3200–3680). In total,
two of the 30 (7%) patients delivered prematurely; one of them
had a twin pregnancy. The preterm twins were born at a gesta-
tional age of 33 weeks with birth weights of 1874 and 1809 g,
while one infant was born at a gestational age of 31 weeks with
a birth weight of 2030 g. Two newborns (6.5%) had congenital
abnormalities, which consisted of a clubfoot and an isolated
ptosis of the left eye. The converted 6-TGN concentrations in
these infants were 77 and 42 pmol/8×108 RBCs, respectively.
DISCUSSION
Our study demonstrates that pregnancy has an important effect
on maternal thiopurine metabolism, leading to decreased
6-TGN and increased 6-MMP concentrations during stable
dosing of thiopurines. The fetus is exposed to 6-TGN, with con-
centrations that correlate strongly with maternal 6-TGN concen-
trations. Remarkably, in only one infant, who was diagnosed
with myelosupression and liver function test abnormalities at
birth, was 6-MMP detected. Mild anaemia was observed directly
after birth in 60% of the newborns.
During pregnancy, a decrease in median 6-TGN concentration
was observed, while 6-MMP levels increased. This alteration in
thiopurine metabolism did not lead to biochemical toxicity or
adverse events in the mothers. After delivery, both 6-TGN and
6-MMP levels returned to baseline. Previous studies have shown
that hormonal changes during pregnancy may influence drug-
metabolising enzymes.22 23 An increase in thiopurine S-methyl
transferase (TPMT) activity during pregnancy, causing preferen-
tial metabolism of MP to 6-MMP at the expense of 6-TGN for-
mation, may explain the decrease in 6-TGN and increase in
Table 2 Pharmacokinetics of thiopurine use during pregnancy
6-TGN (Lennard method) 6-TGN (Dervieux method) 6-MMP 6-MMP/6-TGN ratio (Lennard method)
Pre-conception 115 (81–198) 280 (210–550) 1290 (584–2790) 10.9 (4.2–24.4)
After pregnancy confirmation 106 (70–166) 270 (190–380) 2140 (820–4548) 22.6 (9.1–37.4)
Gestational week 13.5 85 (56–158) 220 (130–500) 2330 (615–4390) 27.9 (4.8–48.5)
Gestational week 26.5 98 (77–169) 230 (170–260) 2648 (468–5888) 27.1 (3.1–78.1)
Delivery 92 (73–113) 240 (210–290) 2390 (268–6588) 20.3 (1.3–90.1)
3 months after delivery 102 (78–133) 270 (190–550) 1090 (518–3590) 13.8 (5.1–27.5)
Values are median (IQR).
6-TGN levels are depicted according to both methods (Lennard and Dervieux). For the 6-MMP/6-TGN ratio, we used the converted outcomes (comparable with data generated when
using the method of Lennard).
6-MMP, 6-methylmercaptopurine (pmol/8×108 red blood cells); 6-TGN, 6-thioguanine nucleotide (pmol/8×108 red blood cells).
Figure 2 Maternal 6-methylmercaptopurine (6-MMP) levels. An
increase in median maternal 6-MMP levels (indicated by horizontal
lines) was observed during pregnancy, which was not significant
(p=0.183). After delivery, 6-MMP levels returned to baseline
concentrations (Wilcoxon, T=0 vs T=5, p>0.05). 6-MMP concentration
(pmol/8×108 red blood cells (RBC)) is depicted on the y-axis. T=0,
before conception; T=1, directly after pregnancy confirmation; T=2,
after the first trimester; T=3, after the second trimester; T=4, delivery;
T=5, 3 months after delivery.
Figure 3 Maternal 6-methylmercaptopurine (6-MMP)/6-thioguanine
nucleotide (6-TGN) ratios. A significant increase in median maternal
6-MMP/6-TGN ratio (indicated by horizontal lines) was observed during
pregnancy (p=0.007). After delivery, it returned to baseline levels
(Wilcoxon, T=0 vs T=5, p>0.05). 6-MMP/6-TGN ratio is depicted on the
y-axis. T=0, before conception; T=1, directly after pregnancy
confirmation; T=2, after the first trimester; T=3, after the second
trimester; T=4, delivery; T=5, 3 months after delivery. The 6-TGN
concentrations are expressed in converted values (comparable with
data generated according to the method of Lennard).
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6-MMP. As thiopurine metabolite levels are the essential
pharmacological end products of the complex thiopurine metab-
olism, these levels were measured during pregnancy rather than
possible changes in TPMT or other thiopurine-metabolising
enzyme activities. Of note, as all the ratios of the metabolite
concentrations of 6-MMP and 6-TGN at baseline were within
4–11 and all mothers tolerated the drug well before inclusion in
the study, we virtually excluded abnormally low TPMT activity
due to mutant TPMT alleles (genotype) in our cohort.
However, no definite conclusions can be drawn on the basis of
our study design about how exactly thiopurine metabolism is
altered during pregnancy.
The risk of developing biochemical signs of hepatotoxicity
has been shown to increase when 6-MMP levels exceed
5700 pmol/8×108 RBCs in non-pregnant patients with IBD.24
A 6-MMP level above 5700 pmol/8×108 RBCs was measured in
26% of our patients during pregnancy, but none developed liver
function test abnormalities. It has been suggested that the
6-MMP/6-TGN ratio may be a predictor of therapeutic efficacy,
as a ratio above 11 has been associated with therapeutic
inefficacy.24 Although the median 6-MMP/6-TGN ratio was
above 11 during pregnancy, none of the women in our series
had a clinical relapse of IBD.
Our study confirms that the fetus is exposed to 6-TGN
during maternal use of thiopurines during pregnancy. Data on
the transfer of thiopurines or its metabolites across the placenta
are limited. Saarikoski and Seppala25 demonstrated that the
parent drug, AZA, and its inactive metabolite, thiouric acid,
can pass through the human placenta, as both compounds were
found in fetal blood after administration of radioactively
labelled AZA to three pregnant women. Interestingly, AZA and
MP concentrations in the fetal blood were 1–5% and 1–2%,
respectively, compared with maternal blood levels, which sug-
gests that the placenta serves as a barrier to thiopurines and its
metabolites.25 In line with this, Hutson and colleagues26
showed, in a dually perfused experimental placenta model, that
maternal pharmacokinetics and placental binding limit the
transfer of MP from mother to child. They also demonstrated
that the placenta has limited capacity to convert MP into
pharmacologically active metabolites, which suggests that the
maternally derived metabolites cross the placental barrier and
not the parent drug. In our study, there was no difference in
6-TGN concentration in blood from the umbilical vein com-
pared with that from the umbilical artery, which may indicate
that no additional thiopurine metabolism takes place in the
fetus.27 28 However, we need to be cautious in drawing any
conclusions about this on the basis of our study design and
outcomes. As fetal 6-TGN levels correlated strongly with
maternal 6-TGN concentrations, therapeutic drug monitoring
in pregnant women should perhaps be considered to avoid
extremely elevated maternal and fetal 6-TGN levels and thus
potential thiopurine toxicity.
No 6-MMP levels were detected in 24 of the 25 infants.
Remarkably, one child had a 6-MMP level of 1290 pmol/8×108
RBCs, allegedly inducing pancytopenia and a 10-fold increase
in AP activity. His mother had severe pre-eclampsia during preg-
nancy, which resulted in hospital admittance and an emergency
caesarian section at 38 weeks of gestation. Pre-eclampsia may
cause erythrocythaemia and severe thrombocytopenia in new-
borns or fetal hyperviscosity–polycythaemia syndrome, all asso-
ciated with increased placental leakage and impaired
function.29 30 The pre-eclampsia in our patient may have
resulted in increased permeability or disturbed semipermeability
of the placental barrier to 6-MMP.31 Therefore, although specu-
lative, the myelotoxicity in the above described newborn may be
explained by the inhibition of de novo purine synthesis, caused
by the presence of methylated MP derivatives (6-MMP).32 33
Sixty per cent of all the infants exposed to maternal thiopur-
ine use during pregnancy had anaemia at birth. There are many
possible reasons for this, considering that the mothers had IBD
and often took concomitant medication, and many other poten-
tial causes. However, the common denominator, maternal thio-
purine use, and the demonstrated intrauterine exposure to
6-TGN (and potentially other thiopurine metabolites) are the
most obvious explanations. Therefore, we recommend that all
children of thiopurine-using mothers should be tested for pos-
sible anaemia after birth.
In this study, median gestational age and birth weight were
within normal ranges compared with the data from the 10-year
perinatal prospective registration in the Netherlands.34 Two
women (7%) delivered prematurely, which is a lower rate than
the 21.8% reported in a recent French collaborative study that
evaluated pregnancy outcome of women with IBD exposed to
thiopurines.7 The prevalence of congenital abnormalities of
Figure 4 Correlation between 6-thioguanine nucleotide (6-TGN) levels
in mother and child. There was a strong correlation (p<0.0001)
between 6-TGN concentration (pmol/8×108 red blood cells) in the
mother at the time of delivery (y-axis) and in the infant (x-axis). 6-TGN
concentrations are expressed in converted values (comparable with
data generated by the method of Lennard).
Table 3 Change in thiopurine metabolite levels before, during
and after pregnancy
Time Δ6-TGN† (%) Δ6-MMP (%) Δ6-MMP/6-TGN† ratio (%)
T=0 and T=1 −9 (8%) +850 (66%) +12 (107%)
T=0 and T=2 −30 (26%)* +1040 (81%) +17 (156%)*
T=0 and T=3 −17 (15%) +1358 (105%) +16 (149%)*
T=0 and T=4 −23 (20%) +1100 (85%) +9 (86%)
T=0 and T=5 −13 (11%) −200 (16%) +3 (27%)
Post hoc analysis of thiopurine metabolite concentration during pregnancy and post
partum compared with prepregnancy values, expressed as an absolute number (in
pmol/8×108 red blood cells) and percentage. T=0, before conception; T=1, directly
after pregnancy confirmation; T=2, after the first trimester; T=3, after the second
trimester; T=4, delivery; T=5, 3 months after delivery.
*p<0.05.
†Converted 6-TGN levels are used.
6-MMP, 6-methylmercaptopurine; 6-TGN, 6-thioguanine nucleotide.
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6.5% in our study is higher than that of the average Dutch
population and the reported 3.6% in the thiopurine-using IBD
cohort from France.7 However, the data on pregnancy
outcome in our study are limited by the small sample of
patients with IBD included, which may explain the conflicting
data with regard to other larger studies. Considering the rela-
tively high rate of miscarriage and spontaneous abortions
(24%) in our series, which are in line with previously reported
data, further investigation of risk factors seems warranted.7
Importantly, the observed (high) percentage of miscarriage and
spontaneous abortions in this study could not be related to
(toxic) levels of thiopurine metabolites.
In conclusion, this study demonstrates that pregnancy has a
major effect on thiopurine metabolism, leading to a decrease in
6-TGN and an increase in 6-MMP levels without causing myelo-
toxicity or hepatotoxicity. The fetus is exposed in utero to
6-TGN during maternal thiopurine use. 6-MMP was detected in
only one child, probably because of placental insufficiency,
whereas all other children had undetectable concentrations of
6-MMP at birth. Although all infants were exposed to 6-TGN,
no major teratogenicity was observed. Sixty per cent of the
infants had anaemia, probably due to maternal thiopurine use.
The strong correlation between fetal and maternal 6-TGN con-
centration suggests that potentially toxic fetal 6-TGN levels can
be avoided by monitoring maternal thiopurine metabolite con-
centration during pregnancy. In addition, our results raise the
question whether all infants exposed to maternal thiopurine use
during pregnancy should be routinely examined for signs of
anaemia immediately after birth.
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